Cryolife (CRY) versus NuVasive (NUVA) Head to Head Review

Cryolife (NYSE: CRY) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Institutional and Insider Ownership

How to Become a New Pot Stock Millionaire

74.1% of Cryolife shares are owned by institutional investors. 6.0% of Cryolife shares are owned by company insiders. Comparatively, 1.2% of NuVasive shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cryolife and NuVasive’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cryolife 1.95% 5.93% 3.55%
NuVasive 8.06% 13.40% 6.20%

Earnings & Valuation

This table compares Cryolife and NuVasive’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cryolife $189.70 million 3.48 $3.70 million $0.40 49.38
NuVasive $1.03 billion 2.71 $83.00 million $1.91 28.49

NuVasive has higher revenue and earnings than Cryolife. NuVasive is trading at a lower price-to-earnings ratio than Cryolife, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cryolife and NuVasive, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cryolife 0 0 3 0 3.00
NuVasive 0 5 11 0 2.69

Cryolife presently has a consensus price target of $25.83, indicating a potential upside of 30.80%. NuVasive has a consensus price target of $66.80, indicating a potential upside of 22.75%. Given Cryolife’s stronger consensus rating and higher probable upside, research analysts clearly believe Cryolife is more favorable than NuVasive.

Volatility & Risk

Cryolife has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

About Cryolife

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.

About NuVasive

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply